Taxane-containing regimens for metastatic breast cancer

Abstract

BackgroundIt is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. This is an update of a Cochrane review first published in 2003. ObjectivesThe objective of this review was to compare taxane-containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer. Search methodsIn this review update, we searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, EMBASE, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 14 February 2013 using keywords such as 'advanced breast cancer' and 'chemotherapy'. We searched reference lists of articles, contacted study authors, and did not apply any language restrictions. Selection criteriaRandomised controlled trials comparing taxane-containing chemotherapy regimens to regimens without taxanes in women with metastatic breast cancer. We included published and unpublished studies. Data collection and analysisTwo review authors independently assessed trial quality and extracted data. We derived hazard ratios (HRs) for overall survival, time to progression, and time to treatment failure where possible, and used a fixed-e ect model for meta-analysis. We represented objective tumour response rates and toxicity as risk ratios (RRs). We extracted quality of life data where present. Main resultsThis review included 28 studies. The updated analysis included 6871 randomised women, while the original review had 3643 women. Of the 28 included studies, we considered 19 studies to be at low risk of bias overall; however, some studies failed to report details on allocation concealment and methods of outcome assessment for those outcomes that are more likely to be influenced by a lack of blinding Taxane-containing regimens for metastatic breast cancer (Review)

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

“…Currently, taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and combination schedules, with a proven survival benefit compared with the use of other types of chemotherapy. Paclitaxel and docetaxel, the two most commonly used taxanes against breast cancer, are the agents of choice in patients progressing after anthracycline-containing chemotherapy according to the most recent international guidelines [Ghersi et al 2003;Cardoso et al 2014]. These two agents were both registered as 3-weekly (q3w) regimens, but different doses and schedules were subsequently tested aiming at increasing efficacy and at reducing the burden of treatment-related toxicity.…”

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

“…A 2005 meta-analysis from the Cochrane Collaboration noted that when all trials are considered, taxane-containing regimens appear to improve os, ttp, and overall response in women with metastatic breast cancer 63 . Another meta-analysis found that, although there are potential differences in rr and pfs, taxanes are equivalent to anthracyclines (either as single agents or in combination) in terms of os benefit 64 .…”

Adverse reactions to docetaxel: an active survey

“…It has been used to treat various tumors, particularly tumors of the breast (Bear et al, 2003;Jones et al, 2006), lung (Noble et al, 2006) and prostate (Kelly et al, 2009). Its use can bring benefits such as increasing life expectancy and decreasing tumors, tumor progression and risk of relapse (Ghersi et al, 2015). It is used as a first-line therapeutic treatment in combination with trastuzumab, a monoclonal antibody specific for HER2 receptor in metastatic breast cancers that express the HER2 receptor.…”